PL367287A1 - Use of proteasome inhibitors to treat dry eye disorders - Google Patents
Use of proteasome inhibitors to treat dry eye disordersInfo
- Publication number
- PL367287A1 PL367287A1 PL02367287A PL36728702A PL367287A1 PL 367287 A1 PL367287 A1 PL 367287A1 PL 02367287 A PL02367287 A PL 02367287A PL 36728702 A PL36728702 A PL 36728702A PL 367287 A1 PL367287 A1 PL 367287A1
- Authority
- PL
- Poland
- Prior art keywords
- dry eye
- proteasome inhibitors
- eye disorders
- treat dry
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 title abstract 2
- 206010013774 Dry eye Diseases 0.000 title abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 title abstract 2
- 239000003207 proteasome inhibitor Substances 0.000 title abstract 2
- 238000009736 wetting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29272201P | 2001-05-21 | 2001-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL367287A1 true PL367287A1 (en) | 2005-02-21 |
Family
ID=23125916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02367287A PL367287A1 (en) | 2001-05-21 | 2002-05-17 | Use of proteasome inhibitors to treat dry eye disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6740674B2 (enExample) |
| EP (1) | EP1392355B1 (enExample) |
| JP (1) | JP2004530699A (enExample) |
| CN (1) | CN1509183A (enExample) |
| AT (1) | ATE353667T1 (enExample) |
| AU (1) | AU2002308760B2 (enExample) |
| BR (1) | BR0209883A (enExample) |
| CA (1) | CA2447909C (enExample) |
| CY (1) | CY1107531T1 (enExample) |
| DE (1) | DE60218153T2 (enExample) |
| DK (1) | DK1392355T3 (enExample) |
| ES (1) | ES2278049T3 (enExample) |
| MX (1) | MXPA03010634A (enExample) |
| PL (1) | PL367287A1 (enExample) |
| PT (1) | PT1392355E (enExample) |
| WO (1) | WO2002094311A1 (enExample) |
| ZA (1) | ZA200308768B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
| US7465720B2 (en) | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
| ES2415756T3 (es) | 2005-11-09 | 2013-07-26 | Onyx Therapeutics, Inc. | Compuestos para la inhibición de enzimas |
| ES2415632T3 (es) | 2006-06-19 | 2013-07-26 | Onyx Therapeutics, Inc. | Epoxicetonas peptídicas para la inhibición del proteosoma |
| EP2207791B2 (en) | 2007-10-04 | 2019-08-07 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| EA024364B1 (ru) | 2008-10-21 | 2016-09-30 | Оникс Терапьютикс, Инк. | Способ лечения множественной миеломы |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| EP2542238B1 (en) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| BR112012025264A2 (pt) | 2010-04-07 | 2019-09-24 | Onyx Therapeutics Inc | inibidor de imunoproteassoma de e´poxicetona peptídica cristalina. |
| US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| UY34897A (es) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | Profarmacos de inhibidores peptidicos de expoxi cetona proteasa |
| CN103893742B (zh) * | 2014-03-03 | 2016-01-20 | 中山大学中山眼科中心 | 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用 |
| CN107151255A (zh) * | 2016-03-06 | 2017-09-12 | 复旦大学 | 硼酸类化合物及其制备方法和用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991759A (en) | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
| US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4370325A (en) | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
| US4744980A (en) | 1986-04-28 | 1988-05-17 | Holly Frank J | Ophthalmic solution for treatment of dry eye syndrome |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4818537A (en) | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
| US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5583150A (en) | 1989-08-18 | 1996-12-10 | Alcon Laboratories, Inc. | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases |
| US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| US5958912A (en) | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
| WO1993020823A1 (en) | 1992-04-21 | 1993-10-28 | The Schepens Eye Research Institute, Inc. | Ocular androgen therapy in sjögren's syndrome |
| US6107289A (en) | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US5290572A (en) | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| JPH1036289A (ja) | 1996-07-24 | 1998-02-10 | Sumitomo Pharmaceut Co Ltd | 神経細胞の変性または死滅抑制剤 |
| US6071904A (en) | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| CN1159061C (zh) | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
| EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CA2219867A1 (en) | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| BR9906772A (pt) | 1998-07-14 | 2000-09-26 | Alcon Lab Inc | Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular |
| US6096733A (en) | 1998-12-10 | 2000-08-01 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| WO2000043000A1 (en) | 1999-01-20 | 2000-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Proteasome inhibitors |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| JP2002543058A (ja) | 1999-04-27 | 2002-12-17 | ノバルティス アクチエンゲゼルシャフト | プロテアソーム・インヒビターとしての２，４−ジアミノ−３−ヒドロキシカルボン酸誘導体の使用 |
-
2002
- 2002-05-17 BR BR0209883-0A patent/BR0209883A/pt not_active Application Discontinuation
- 2002-05-17 AU AU2002308760A patent/AU2002308760B2/en not_active Ceased
- 2002-05-17 CA CA2447909A patent/CA2447909C/en not_active Expired - Fee Related
- 2002-05-17 EP EP02771849A patent/EP1392355B1/en not_active Expired - Lifetime
- 2002-05-17 PT PT02771849T patent/PT1392355E/pt unknown
- 2002-05-17 MX MXPA03010634A patent/MXPA03010634A/es active IP Right Grant
- 2002-05-17 PL PL02367287A patent/PL367287A1/xx not_active Application Discontinuation
- 2002-05-17 WO PCT/US2002/015775 patent/WO2002094311A1/en not_active Ceased
- 2002-05-17 JP JP2002591027A patent/JP2004530699A/ja active Pending
- 2002-05-17 ES ES02771849T patent/ES2278049T3/es not_active Expired - Lifetime
- 2002-05-17 DE DE60218153T patent/DE60218153T2/de not_active Expired - Lifetime
- 2002-05-17 US US10/150,191 patent/US6740674B2/en not_active Expired - Lifetime
- 2002-05-17 DK DK02771849T patent/DK1392355T3/da active
- 2002-05-17 CN CNA028098544A patent/CN1509183A/zh active Pending
- 2002-05-17 AT AT02771849T patent/ATE353667T1/de active
-
2003
- 2003-11-11 ZA ZA2003/08768A patent/ZA200308768B/en unknown
-
2007
- 2007-03-13 CY CY20071100343T patent/CY1107531T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010634A (es) | 2004-03-09 |
| DE60218153T2 (de) | 2007-06-28 |
| CA2447909C (en) | 2011-04-05 |
| US6740674B2 (en) | 2004-05-25 |
| BR0209883A (pt) | 2004-06-08 |
| US20030008910A1 (en) | 2003-01-09 |
| ATE353667T1 (de) | 2007-03-15 |
| ZA200308768B (en) | 2005-01-26 |
| WO2002094311A1 (en) | 2002-11-28 |
| CY1107531T1 (el) | 2013-03-13 |
| CN1509183A (zh) | 2004-06-30 |
| ES2278049T3 (es) | 2007-08-01 |
| CA2447909A1 (en) | 2002-11-28 |
| JP2004530699A (ja) | 2004-10-07 |
| EP1392355A1 (en) | 2004-03-03 |
| PT1392355E (pt) | 2007-03-30 |
| DE60218153D1 (de) | 2007-03-29 |
| DK1392355T3 (da) | 2007-04-30 |
| AU2002308760B2 (en) | 2006-05-11 |
| EP1392355B1 (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
| AU2002305756A8 (en) | Use of nf-kappa-b inhibitors to treat dry eye disorders | |
| BR0314603A (pt) | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos | |
| DE60022692D1 (de) | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen | |
| MY135732A (en) | 5,6-trimethylenepyrimidin - 4 - one compounds | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| ATE247117T1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| MXPA03011985A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| AU3831301A (en) | Method for treating ocular pain | |
| PL350291A1 (en) | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
| NZ525103A (en) | Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders | |
| MY136037A (en) | Biphenyl pyrimidone lp-pla2 inhibitors | |
| EP1337255A4 (en) | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH | |
| MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| PL367286A1 (en) | Use of nfkb inhibitors to treat dry eye disorders | |
| MXPA03000313A (es) | Uso de fosfato de estramustina en el tratamiento de metastasis osea. | |
| ZA200609220B (en) | Method of treating dry eye disorders and uveitis | |
| AU2002347984A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
| SG144942A1 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| GB9626472D0 (en) | New use of comt inhibitors | |
| YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| MXPA05010800A (es) | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos. | |
| MY140194A (en) | Novel fusidic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |